Industry news

New laser and synchrotron upgrades promise stronger UK research capabilities, even as funding pressures lead to shorter operating cycles and reduced access at some facilities.

Oxford-based OMass Therapeutics has raised £230 million to advance its clinical pipeline, highlighting the role of native mass spectrometry in discovering treatments for rare disorders.

Stockport NHS Foundation Trust’s blood science laboratory has achieved My Green Lab Gold certification after changes to daily workflows addressing energy use and single-use plastics.

A bespoke high-throughput platform cut optimisation from weeks to hours and increased productivity fivefold, while automation also improves powder handling and routine laboratory data management.

A trial of engineered regulatory T cells for severe autoimmune conditions has advanced to its second dose cohort, highlighting progress in cell-therapy research and delivery.

Sustainability in LC-MS is most often discussed in terms of solvent consumption, and for good reason. Liquid chromatography relies heavily on mobile phases, frequently containing acetonitrile or methanol, which must be manufactured, transported, stored and eventually disposed of as chemical waste.

LinkedIn has once again changed the way it ranks and serves up content to users. Here, The Scott Partnership examines how and why the algorithms have changed, and how labs can adjust their approach to stay one step ahead.

Every leader wants to talk about AI. Fewer want to talk about what has to happen before AI can be applied. Most labs aren’t ready to “do AI” in any meaningful way – not because the models aren’t good enough, but because the data those models would need is scattered, siloed, poorly contextualised, and locked inside proprietary formats. If you want to play the AI end game, you first have to build the foundation underneath it: universal data accessibility.

The mass spectrometry (MS) data systems market reached USD $413M in 2023, with growth forecasted to reach USD $560M by 2028. (1) This expansion is driven primarily by the growth of the pharmaceutical and biopharmaceutical industries, public and environmental health concerns, growing government investment, and the integration of artificial intelligence (AI). (2)